192 related articles for article (PubMed ID: 38396211)
21. A special report: bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world--1994 update. The WMDA Executive Committee.
Goldman JM
Blood; 1994 Nov; 84(9):2833-9. PubMed ID: 7949160
[TBL] [Abstract][Full Text] [Related]
22. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
23. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
[No Abstract] [Full Text] [Related]
24. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
25. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
26. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
[TBL] [Abstract][Full Text] [Related]
27. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products.
Horan A; Warreth S; Hervig T; Waters A
Cytotherapy; 2024 May; 26(5):524-530. PubMed ID: 38441513
[TBL] [Abstract][Full Text] [Related]
28. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry.
Schmidt AH; Sauter J; Schetelig J; Neujahr E; Pingel J
Best Pract Res Clin Haematol; 2024 Mar; 37(1):101541. PubMed ID: 38490766
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world. The Executive Committee of the World Marrow Donor Association.
Bone Marrow Transplant; 1992 Sep; 10(3):287-91. PubMed ID: 1422482
[TBL] [Abstract][Full Text] [Related]
30. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
31. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.
Qiu T; Wang Y; Liang S; Han R; Toumi M
Drug Discov Today; 2021 Oct; 26(10):2269-2281. PubMed ID: 33892148
[TBL] [Abstract][Full Text] [Related]
32. Donor work-up and transport of bone marrow--recommendations and requirements for a standardized practice throughout the world from the Donor Registries and Quality Assurance Working Groups of the World Marrow Donor Association (WMDA).
Cleaver SA; Warren P; Kern M; Hurley CK; Raffoux C; Keller J; Kiesel U; Koza V; Marry E; Mitterschiffthaler A; Nakamura M; Okah CT; Persson U; Radde-Stepaniak T; Ranson L; Raymond J; do Rosario Sancho M; Varla-Leftherioti M; Wiegand T; Winterhager JM; Woodfield DG
Bone Marrow Transplant; 1997 Oct; 20(8):621-9. PubMed ID: 9383224
[TBL] [Abstract][Full Text] [Related]
33. Overview of registries, HLA typing and diversity, and search algorithms.
Hurley CK; Maiers M; Marsh SG; Oudshoorn M
Tissue Antigens; 2007 Apr; 69 Suppl 1():3-5. PubMed ID: 17445151
[TBL] [Abstract][Full Text] [Related]
34. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
35. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
[TBL] [Abstract][Full Text] [Related]
36. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
Lowdell MW; Thomas A
Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
[TBL] [Abstract][Full Text] [Related]
37. Cell, tissue and gene products with marketing authorization in 2018 worldwide.
Cuende N; Rasko JEJ; Koh MBC; Dominici M; Ikonomou L
Cytotherapy; 2018 Nov; 20(11):1401-1413. PubMed ID: 30366616
[TBL] [Abstract][Full Text] [Related]
38. Gene and cell therapy for children--new medicines, new challenges?
Buckland KF; Bobby Gaspar H
Adv Drug Deliv Rev; 2014 Jun; 73(100):162-9. PubMed ID: 24583376
[TBL] [Abstract][Full Text] [Related]
39. Informed consent--suggested procedures for informed consent for unrelated haematopoietic stem cell donors at various stages of recruitment, donor evaluation, and donor workup.
Rosenmayr A; Hartwell L; Egeland T;
Bone Marrow Transplant; 2003 Apr; 31(7):539-45. PubMed ID: 12692618
[TBL] [Abstract][Full Text] [Related]
40. Central Unrelated Potential Bone Marrow and Cord Blood Registry in Poland: Structure and Numbers.
Nestorowicz K; Dudkiewicz M; Czerwiński J; Łęczycka A; Macher M; Kamiński A
Transplant Proc; 2020 Sep; 52(7):2011-2014. PubMed ID: 32499141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
